Imricor Medical Systems Inc (ASX: IMR) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Imricor Medical Systems Inc. Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $176.18 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 143.23 million
Earnings per share -0.134
Dividend per share N/A
Year To Date Return -44.69%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Imricor Medical Systems Inc (ASX: IMR)
Latest News

IMR ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About Imricor Medical Systems Inc

Imricor Medical Systems Inc is a medical device company engaged in addressing issues with traditional x-ray-guided ablation procedures through the development of MRI-guided technology. The products of the company include Advantage-MR EP Recorder / Stimulator, Vision-MR Ablation Catheter and Vision-MR Dispersive Electrode.

IMR Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
25 Nov 2021 $1.23 $-0.02 -1.60% 24,330 $1.22 $1.23 $1.22
24 Nov 2021 $1.25 $-0.10 -7.41% 18,465 $1.37 $1.37 $1.22
23 Nov 2021 $1.35 $0.19 16.38% 292,157 $1.21 $1.35 $1.18
22 Nov 2021 $1.16 $-0.07 -5.69% 1,225,397 $1.23 $1.25 $1.14
19 Nov 2021 $1.23 $-0.03 -2.38% 45,407 $1.26 $1.26 $1.23
18 Nov 2021 $1.26 $0.02 1.61% 23,881 $1.25 $1.26 $1.24
17 Nov 2021 $1.24 $0.00 0.00% 15,622 $1.25 $1.25 $1.24
16 Nov 2021 $1.24 $-0.06 -4.62% 107,337 $1.30 $1.30 $1.24
15 Nov 2021 $1.30 $0.00 0.00% 18,436 $1.30 $1.32 $1.30
12 Nov 2021 $1.30 $0.03 2.35% 4,000 $1.30 $1.30 $1.30
11 Nov 2021 $1.28 $0.07 5.81% 30,009 $1.20 $1.28 $1.20
10 Nov 2021 $1.21 $-0.06 -4.74% 26,680 $1.22 $1.23 $1.21
09 Nov 2021 $1.27 $-0.01 -0.79% 1,077,590 $1.25 $1.27 $1.22
08 Nov 2021 $1.27 $-0.02 -1.54% 357,882 $1.29 $1.30 $1.26
05 Nov 2021 $1.30 $0.00 0.00% 79,333 $1.29 $1.31 $1.28
04 Nov 2021 $1.29 $-0.01 -0.77% 24,714 $1.31 $1.31 $1.29
03 Nov 2021 $1.30 $0.00 0.00% 107,878 $1.27 $1.30 $1.24
02 Nov 2021 $1.30 $0.02 1.56% 106,609 $1.30 $1.31 $1.25
01 Nov 2021 $1.28 $-0.07 -5.19% 64,263 $1.30 $1.30 $1.20
29 Oct 2021 $1.35 $0.06 4.65% 23,821 $1.35 $1.35 $1.27
28 Oct 2021 $1.29 $-0.14 -9.79% 261,073 $1.42 $1.43 $1.25
27 Oct 2021 $1.43 $-0.01 -0.69% 60,186 $1.46 $1.46 $1.43

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
07 May 2021 Peter McGregor Issued 40 $81,792
Issue of options.
07 May 2021 Steve Wedan Issued 304 $608,508
Issue of options.
07 May 2021 Mark Tibbles Issued 40 $81,792
Issue of options.
07 May 2021 Anita Messal Issued 38 $76,680
Issue of options.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Peter McGregor Non-Executive Director May 2019
Mr McGregor has over 30 years' experience in senior finance and management roles, including having been a partner in the investment banking firm of Goldman Sachs JBWere and a managing director in the institutional banking & markets division of Commonwealth Bank of Australia. He is Chair of Risk Committee.
Mr Steve Wedan Chief Executive OfficerPresidentExecutive ChairmanExecutive Director May 2006
Mr Wedan is in charge for the overall management and strategic direction of the Company. Mr Wedan has over 29 years of experience in the medical device industry including design engineering of MRI and ultrasound systems for GE Healthcare, as well as Vice President and Chief Technology Officer for Applied Biometrics Inc. Immediately prior to co-founding Imricor, Mr Wedan founded and operated a technical consulting company, Wedan Technologies Inc., from 2000-2006. Mr Wedan is a member of range of international standards committees in the fields of MRI safety and the compatibility of implanted and interventional products in MRI. Mr Wedan currently serves on the boards of Medical Device Research Forum and Water Rescue Innovations, Inc.
Mr Mark Tibbles Non-Executive Director Sep 2014
Mr Tibbles is an entrepreneur, business owner, company director and active venture investor in and advisor to technology, life science and medical device companies. Mr Tibbles is currently the Managing Director of Strategic Stage Ventures, LLC and an owner and managing member of STEM Fuse. Prior to his current roles, Mr Tibbles was an owner and member of Intuitive Technology Group until it was sold in 2017. Mr Tibbles was also President and founder of PRC Consulting, Inc. from 1998 until 2013, when PRC was sold. Mr Tibbles currently serves as an independent director of OMEDZA.com, Inc. He is Member of Risk Committee.
Ms Anita Messal Non-Executive Director Mar 2021
Ms Messal has 35 years of experience in the healthcare sector and is currently the Chief Integration Officer at AccentCare,Inc. a US based national post-acute healthcare provider, where she is responsible for the integration of merged and acquired entities across all areas of the business. Prior to AccentCare, she most recently served as President & Chief Operating Officer of PlanSource. In this role, she was responsible for company technology & operations including all aspects of Technology, Product, Service Delivery, Legal, and Human Resources. Ms Messal has participated in fund raising from start-up through IPO and sale to strategic buyers and private equity. She has worked in both Fortune 100 and start-up companies with experience in public, private and non-profit businesses. Her experience includes working in domestic and international markets, where she involved in developing programs and partnerships in the United Kingdom and the European Union.
Mr Kobe Li Company Secretary
-
Lori Milbrandt Chief Financial Officer
-
Gregg Stenzel Chief Operating Officer
-
Kobe Li Company Secretary
-
Nick Twohy Executive Director of Marketing
-
Greg Englehardt Executive Director of Sales
-
Tom Lloyd Vice President of Clinical Research
-
Dan Sunnarborg Vice President of Engineering
-
Jennifer Weisz Vice President of Regulatory and Quality
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
No Top 20 Shareholder Information 0 0.00%

Profile

since

Note